BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cooper R, Sarioğlu S, Sökmen S, Füzün M, Küpelioğlu A, Valentine H, Görken IB, Airley R, West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003;89:870-6. [PMID: 12942120 DOI: 10.1038/sj.bjc.6601202] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene. 2006;25:4663-4674. [PMID: 16892080 DOI: 10.1038/sj.onc.1209604] [Cited by in Crossref: 391] [Cited by in F6Publishing: 364] [Article Influence: 24.4] [Reference Citation Analysis]
2 Harshani JM, Yeluri S, Guttikonda VR. Glut-1 as a prognostic biomarker in oral squamous cell carcinoma. J Oral Maxillofac Pathol 2014;18:372-8. [PMID: 25948991 DOI: 10.4103/0973-029X.151318] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
3 Liu Y, Zhang W, Cao Y, Liu Y, Bergmeier S, Chen X. Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms. Cancer Lett. 2010;298:176-185. [PMID: 20678861 DOI: 10.1016/j.canlet.2010.07.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
4 Legan M, Luzar B, Marolt VF. Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scandinavian Journal of Gastroenterology 2009;44:1101-8. [DOI: 10.1080/00365520903121685] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li YC, Yang CS, Zhou WL, Li HS, Han YJ, Wang QS, Wu HB. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. World J Gastroenterol 2018; 24(4): 494-503 [PMID: 29398870 DOI: 10.3748/wjg.v24.i4.494] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C. Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Mol Membr Biol 2011;28:182-6. [PMID: 21332301 DOI: 10.3109/09687688.2011.554447] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
7 Zhou SH, Fan J, Chen XM, Cheng KJ, Wang SQ. Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 2009;31:1624-33. [PMID: 19441091 DOI: 10.1002/hed.21137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
8 Wincewicz A, Sulkowska M, Koda M, Sulkowski S. Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer. Pathol Oncol Res 2007;13:15-20. [PMID: 17387384 DOI: 10.1007/BF02893436] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
9 Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget 2015;6:32748-60. [PMID: 26293674 DOI: 10.18632/oncotarget.4977] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
10 Nobre AR, Entenberg D, Wang Y, Condeelis J, Aguirre-Ghiso JA. The Different Routes to Metastasis via Hypoxia-Regulated Programs. Trends Cell Biol 2018;28:941-56. [PMID: 30041830 DOI: 10.1016/j.tcb.2018.06.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
11 Kubo Y, Aishima S, Tanaka Y, Shindo K, Mizuuchi Y, Abe K, Shirabe K, Maehara Y, Honda H, Oda Y. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Human Pathology 2014;45:1610-7. [DOI: 10.1016/j.humpath.2014.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
12 Sis B, Sarioglu S, Sokmen S, Sakar M, Kupelioglu A, Fuzun M. Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma. J Clin Pathol 2005;58:32-8. [PMID: 15623479 DOI: 10.1136/jcp.2004.018705] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
13 Airley R, Evans A, Mobasheri A, Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Ann Anat 2010;192:133-8. [PMID: 20395120 DOI: 10.1016/j.aanat.2010.03.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
14 Muratori L, Petroni G, Antonuzzo L, Boni L, Iorio J, Lastraioli E, Bartoli G, Messerini L, Di Costanzo F, Arcangeli A. hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. Onco Targets Ther 2016;9:6325-32. [PMID: 27789963 DOI: 10.2147/OTT.S114090] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
15 van Laarhoven HW, Kaanders JH, Lok J, Peeters WJ, Rijken PF, Wiering B, Ruers TJ, Punt CJ, Heerschap A, van der Kogel AJ. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys. 2006;64:473-482. [PMID: 16242253 DOI: 10.1016/j.ijrobp.2005.07.982] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
16 Zeman EM. Biologic Basis of Radiation Oncology. Clinical Radiation Oncology. Elsevier; 2012. pp. 3-42. [DOI: 10.1016/b978-1-4377-1637-5.00001-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich J, Oefner PJ, Kreutz M, Bosserhoff AK, Hellerbrand C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009;174:1544-52. [PMID: 19286567 DOI: 10.2353/ajpath.2009.080596] [Cited by in Crossref: 179] [Cited by in F6Publishing: 184] [Article Influence: 13.8] [Reference Citation Analysis]
18 Doss DM, Nirmal M, Veeravarmal, Saravanan R, Venkatesh A. Evaluating the expression of GLUT-1 in oral leukoplakia. J Oral Maxillofac Pathol 2020;24:308-14. [PMID: 33456240 DOI: 10.4103/jomfp.JOMFP_220_17] [Reference Citation Analysis]
19 Zhang X, Chen L. The recent progress of the mechanism and regulation of tumor necrosis in colorectal cancer. J Cancer Res Clin Oncol 2016;142:453-63. [PMID: 26094047 DOI: 10.1007/s00432-015-1997-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
20 Mascitelli L, Goldstein MR. Long-Standing Statin Therapy and the Risk of New-Onset Diabetes in the Elderly: Collateral Damage Caused by Preventive Medicine? Drugs & Aging 2012;29:9-13. [DOI: 10.2165/11598530-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Goh V, Halligan S, Daley F, Wellsted DM, Guenther T, Bartram CI. Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis? Radiology. 2008;249:510-517. [PMID: 18812560 DOI: 10.1148/radiol.2492071365] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 7.1] [Reference Citation Analysis]
22 Fan J, Zhou JQ, Yu GR, Lu DD. Glucose transporter protein 1-targeted RNA interference inhibits growth and invasion of the osteosarcoma cell line MG63 in vitro. Cancer Biother Radiopharm. 2010;25:521-527. [PMID: 20854211 DOI: 10.1089/cbr.2010.0784] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
23 Goldstein MR, Mascitelli L. Statin-induced diabetes: perhaps, it's the tip of the iceberg. QJM 2011;104:174-8. [DOI: 10.1093/qjmed/hcq230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Pooja VK, Vanishree M, Ravikumar S, Koneru A, Hunasgi S, Surekha R. Evaluation of the orofacial lesions in treated leprosy patients. J Oral Maxillofac Pathol 2014;18:386-9. [PMID: 25948993 DOI: 10.4103/0973-029X.151322] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
25 Furukawa T, Miyata Y, Kushitani K, Mimae T, Tsutani Y, Takeshima Y, Okada M. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer. Jpn J Clin Oncol 2015;45:1154-61. [PMID: 26386467 DOI: 10.1093/jjco/hyv138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
26 Zambrano A, Molt M, Uribe E, Salas M. Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. Int J Mol Sci 2019;20:E3374. [PMID: 31324056 DOI: 10.3390/ijms20133374] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
27 Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy. BMC Cancer. 2010;10:320. [PMID: 20569445 DOI: 10.1186/1471-2407-10-320] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
28 Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-56. [PMID: 17595539 DOI: 10.1159/000104457] [Cited by in Crossref: 228] [Cited by in F6Publishing: 216] [Article Influence: 15.2] [Reference Citation Analysis]
29 Sulkowska M, Wincewicz A, Sulkowski S, Koda M, Kanczuga-Koda L. Relations of TGF-beta1 with HIF-1 alpha, GLUT-1 and longer survival of colorectal cancer patients. Pathology. 2009;41:254-260. [PMID: 19142800 DOI: 10.1080/00313020802579318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
30 Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ, Kay EW. GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer 2009;125:2778-82. [PMID: 19569052 DOI: 10.1002/ijc.24693] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
31 Wincewicz A, Sulkowska M, Koda M, Kanczuga-koda L, Witkowska E, Sulkowski S. Significant Coexpression of GLUT-1, Bcl-xL, and Bax in Colorectal Cancer. Annals of the New York Academy of Sciences 2007;1095:53-61. [DOI: 10.1196/annals.1397.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
32 Petty JC, Lana SE, Thamm DH, Charles JB, Bachand AM, Bush JM, Ehrhart EJ. Glucose transporter 1 expression in canine osteosarcoma. Vet Comparative Oncology 2008;6:133-40. [DOI: 10.1111/j.1476-5829.2007.00155.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
33 Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Letters 2005;221:225-35. [DOI: 10.1016/j.canlet.2004.06.029] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
34 Zeman EM. The Biological Basis of Radiation Oncology. Clinical Radiation Oncology. Elsevier; 2016. pp. 2-40.e5. [DOI: 10.1016/b978-0-323-24098-7.00001-0] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 Banning U, Barthel H, Mauz-korholz C, Kluge R, Korholz D, Sabri O. Effect of drug-induced cytotoxicity on glucose uptake in Hodgkin's lymphoma cells. Eur J Haematol 2006;77:102-8. [DOI: 10.1111/j.1600-0609.2006.00675.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
36 Yip K, Alonzi R. Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol 2013;5:25-34. [PMID: 23372608 DOI: 10.1177/1756287212452195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
37 Shen YM, Arbman G, Olsson B, Sun XF. Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers. 2011;26:166-172. [PMID: 21786248 DOI: 10.5301/jbm.2011.8550] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
38 Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther. 2010;10:729-746. [PMID: 20470005 DOI: 10.1586/era.10.43] [Cited by in Crossref: 133] [Cited by in F6Publishing: 109] [Article Influence: 12.1] [Reference Citation Analysis]
39 Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007;9:1237-94. [PMID: 17571959 DOI: 10.1089/ars.2007.1623] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
40 Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 2005;37:611-703. [PMID: 16393888 DOI: 10.1080/03602530500364023] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 7.1] [Reference Citation Analysis]
41 Kimura Y, Kasamatsu A, Nakashima D, Yamatoji M, Minakawa Y, Koike K, Fushimi K, Higo M, Endo-Sakamoto Y, Shiiba M, Tanzawa H, Uzawa K. ARNT2 Regulates Tumoral Growth in Oral Squamous Cell Carcinoma. J Cancer 2016;7:702-10. [PMID: 27076852 DOI: 10.7150/jca.14208] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
42 Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010;2010. [PMID: 20706540 DOI: 10.1155/2010/205357] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 7.8] [Reference Citation Analysis]
43 Yang J, Wen J, Tian T, Lu Z, Wang Y, Wang Z, Wang X, Yang Y. GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget. 2017;8:11788-11796. [PMID: 28052033 DOI: 10.18632/oncotarget.14352] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
44 Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009;92:317-335. [PMID: 19357959 DOI: 10.1007/s11060-009-9827-2] [Cited by in Crossref: 198] [Cited by in F6Publishing: 195] [Article Influence: 15.2] [Reference Citation Analysis]
45 Azcue P, Guerrero Setas D, Encío I, Ibáñez-Beroiz B, Mercado M, Vera R, Gómez-Dorronsoro ML. A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma. Cancers (Basel) 2021;13:5909. [PMID: 34885019 DOI: 10.3390/cancers13235909] [Reference Citation Analysis]
46 Serganova I, Mayer-Kukuck P, Huang R, Blasberg R. Molecular imaging: reporter gene imaging. Handb Exp Pharmacol 2008;:167-223. [PMID: 18626603 DOI: 10.1007/978-3-540-77496-9_8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
47 Qian Y, Wang X, Chen X. Inhibitors of glucose transport and glycolysis as novel anticancer therapeutics. World J Transl Med 2014; 3(2): 37-57 [DOI: 10.5528/wjtm.v3.i2.37] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
48 Womeldorff M, Gillespie D, Jensen RL. Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma. Neurosurg Focus 2014;37:E8. [PMID: 25581937 DOI: 10.3171/2014.9.focus14496] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
49 Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. FOC 2006;20:E24. [DOI: 10.3171/foc.2006.20.4.16] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
50 Sahoo S, Aurich MK, Jonsson JJ, Thiele I. Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. Front Physiol 2014;5:91. [PMID: 24653705 DOI: 10.3389/fphys.2014.00091] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
51 Guedj N, Bretagnol F, Rautou P, Deschamps L, Cazals-hatem D, Bedossa P, Panis Y, Couvelard A. Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Human Pathology 2011;42:1702-9. [DOI: 10.1016/j.humpath.2011.01.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
52 Legan M, Tevžič Š, Tolar A, Luzar B, Marolt VF. Glucose Transporter-1 (GLUT-1) Immunoreactivity in Benign, Premalignant and Malignant Lesions of the Gallbladder. Pathol Oncol Res 2011;17:61-6. [DOI: 10.1007/s12253-010-9281-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
53 Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung Y, Phillips R, Stubbs M, Griffiths J, Airley R. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 2008;61:377-93. [DOI: 10.1007/s00280-007-0480-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
54 Fan J, Mei J, Zhang MZ, Yuan F, Li SZ, Yu GR, Chen LH, Tang Q, Xian CJ. Clinicopathological significance of glucose transporter protein-1 overexpression in human osteosarcoma. Oncol Lett 2017;14:2439-45. [PMID: 28781680 DOI: 10.3892/ol.2017.6437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Evans CE, Mattock K, Humphries J, Saha P, Ahmad A, Waltham M, Patel A, Modarai B, Porter L, Premaratne S, Smith A. Techniques of assessing hypoxia at the bench and bedside. Angiogenesis 2011;14:119-24. [PMID: 21327472 DOI: 10.1007/s10456-011-9205-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
56 Deandreis D, Leboulleux S, Caramella C, Schlumberger M, Baudin E. FDG PET in the Management of Patients with Adrenal Masses and Adrenocortical Carcinoma. HORM CANC 2011;2:354-62. [DOI: 10.1007/s12672-011-0091-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
57 Zhao ZX, Lu LW, Qiu J, Li QP, Xu F, Liu BJ, Dong JC, Gong WY. Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis. Oncotarget 2018;9:2728-38. [PMID: 29416806 DOI: 10.18632/oncotarget.18964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
58 Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou J, Chen Y, Zheng S, Wang L. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget 2017;8:16875-86. [PMID: 28187435 DOI: 10.18632/oncotarget.15171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 16.8] [Reference Citation Analysis]
59 Mendichovszky I, Jackson A. Imaging hypoxia in gliomas. Br J Radiol 2011;84 Spec No 2:S145-58. [PMID: 22433825 DOI: 10.1259/bjr/82292521] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 5.2] [Reference Citation Analysis]
60 Lastraioli E, Bencini L, Bianchini E, Romoli MR, Crociani O, Giommoni E, Messerini L, Gasperoni S, Moretti R, Di Costanzo F, Boni L, Arcangeli A. hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. Transl Oncol 2012;5:105-12. [PMID: 22496927 DOI: 10.1593/tlo.11250] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
61 Szablewski L. Expression of glucose transporters in cancers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2013;1835:164-9. [DOI: 10.1016/j.bbcan.2012.12.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 203] [Article Influence: 14.4] [Reference Citation Analysis]
62 Komaki S, Sugita Y, Furuta T, Yamada K, Moritsubo M, Abe H, Akiba J, Miyagi N, Nakamura H, Miyoshi H, Ohshima K, Morioka M. Expression of GLUT1 in Pseudopalisaded and Perivascular Tumor Cells Is an Independent Prognostic Factor for Patients With Glioblastomas. J Neuropathol Exp Neurol 2019;78:389-97. [PMID: 30990881 DOI: 10.1093/jnen/nly124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
63 Yang HJ, Xu WJ, Guan YH, Zhang HW, Ding WQ, Rong L, Qiu ZB, Zhong L. Expression of Glut-1 and HK-II in Pancreatic Cancer and Their Impact on Prognosis and FDG Accumulation. Transl Oncol 2016;9:583-91. [PMID: 27916293 DOI: 10.1016/j.tranon.2016.08.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
64 Horton JK, Tepper JE. Staging of colorectal cancer: past, present, and future. Clin Colorectal Cancer 2005;4:302-12. [PMID: 15663833 DOI: 10.3816/ccc.2005.n.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]